Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
SALT LAKE CITY, Oct. 03, 2017 -- Nu-Med Plus, Inc. (OTCBB:NUMD), a medical device company which investigates and develops applications of Nitric Oxide technologies in the medical field has selected Salient Technologies as their strategic product development partner for design of a nitric oxide delivery product for hospital use. This is the final phase for the go to market design that will be submitted to the FDA for approval.
Salient Technologies, Inc. is a creative product development firm with a talented team that helps leading brands and manufacturers with medical device development targeting a competitive edge in the marketplace. They will be working with the NU-MED team moving forward toward FDA submission of their Nitric Oxide Hospital unit.
Inhaled Nitric oxide is a medically essential gas that is presently used in Neonate Hypoxia therapy (inadequate oxygen level in newborns) and may have future applications for a variety of other diseases and complications that are currently being investigated.
“We are excited to have retained Salient Technologies, as we aggressively step forward pursuing FDA clearances and approvals for our Nitric oxide products,“ commented Mr. Jeff Robins, President and CEO of Nu-Med-Plus.
About Nu-Med Plus, Inc.
Nu-Med Plus, Inc. is a medical device development company created to explore medical applications of newly developed technologies. The strategy is to focus on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of inhaled nitric oxide gas for therapeutic use. For more information please visit www.nu-medplus.com.
Contact: Jeff Robins/President 801-746-3570
Forward-Looking Statements
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.
